Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.
| Revenue (TTM) | $10.86B |
| Gross Profit (TTM) | $6.21B |
| EBITDA | $2.40B |
| Operating Margin | 14.60% |
| Return on Equity | 2.94% |
| Return on Assets | 2.80% |
| Revenue/Share (TTM) | $22.21 |
| Book Value | $44.67 |
| Price-to-Book | 1.71 |
| Price-to-Sales (TTM) | 3.33 |
| EV/Revenue | 3.775 |
| EV/EBITDA | 15.03 |
| Quarterly Earnings Growth (YoY) | -44.60% |
| Quarterly Revenue Growth (YoY) | 8.70% |
| Shares Outstanding | $483.40M |
| Float | $481.83M |
| % Insiders | 0.20% |
| % Institutions | 62.06% |
Volatility is currently expanding
Beyond analysts' top-and-bottom-line estimates for Alcon (ALC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
Alcon (ALC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
We seek to purchase our target companies at share prices that incorporate a margin of safety. We estimate that the companies in PSH's investment portfolio will have average annual EPS growth of about 20% over the next three to five years. Our companies also have higher profit margins, better returns on capital, more favorable competitive positioning, and, in our view, more capable management teams than the average company in the S&P 500.
Alcon Inc. remains a Buy, supported by FDA approvals, portfolio-expanding acquisitions, and robust long-term eyecare demand despite recent market underperformance. ALC demonstrates steady revenue growth, improved core EPS guidance, and a pipeline of innovative products targeting high-need clinical niches like glaucoma and macular disease. Balance sheet strength is evident with investment-grade ratings and the lowest D/E ratio among peers, reducing leverage risk and enhancing the risk profile.
GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.
Alcon's acquisitions, partnerships and new product launches support growth, but tariffs and intense competition remain key risks.
Alcon is a structurally advantaged ophthalmology leader with a durable equipment-to-consumables model and strong recurring revenue streams. At $72, ALC trades at ~18x forward earnings, reflecting mid-teens EPS growth but pricing in neither margin expansion nor pipeline optionality. Management targets 25% core operating margin by FY2027E, with current core EPS guidance raised to +12–15% growth and significant capital returns underway.
GENEVA--(BUSINESS WIRE)--Alcon Launches UNITY® M, a Premium Ophthalmic Microscope Delivering Precise Control.
GENEVA--(BUSINESS WIRE)--Alcon Prices EUR 500 Million Senior Notes Offering.
Alcon reported strong core operating profit (barring a one-time non-cash $402 million charge) during the quarter, up 17%. The company raised its full-year 2026 profit forecast for the second consecutive quarter. My DCF valuation states the stock is undervalued by 5.52%. I rate ALC a buy.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ALC and any ticker you trade — then tracks every position and per-strategy win rate.
